Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Total Non-Current Liabilities (2021 - 2025)

Historic Total Non-Current Liabilities for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to $221.4 million.

  • ARS Pharmaceuticals' Total Non-Current Liabilities changed N/A to $221.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.4 million, marking a year-over-year change of. This contributed to the annual value of $94.4 million for FY2024, which is N/A changed from last year.
  • ARS Pharmaceuticals' Total Non-Current Liabilities amounted to $221.4 million in Q3 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Total Non-Current Liabilities peaked at $221.4 million during Q3 2025, and registered a low of $8.5 million during Q4 2022.
  • For the 4-year period, ARS Pharmaceuticals' Total Non-Current Liabilities averaged around $92.1 million, with its median value being $94.4 million (2024).
  • Data for ARS Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY increase of 4847.83% (in 2022) and a maximum YoY decrease of 4847.83% (in 2022) over the last 5 years.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' Total Non-Current Liabilities stood at $16.6 million in 2021, then tumbled by 48.48% to $8.5 million in 2022, then soared by 1003.7% to $94.4 million in 2024, then soared by 134.61% to $221.4 million in 2025.
  • Its Total Non-Current Liabilities stands at $221.4 million for Q3 2025, versus $119.7 million for Q2 2025 and $94.4 million for Q4 2024.